Continuous Combined XXXX Plus @entity1871 and Endometrial Cancer: The @entity1 's Health Initiative Randomized Trial.

@entity172 @entity1 @entity1204 @entity1641 @entity11796 @entity1871 @entity204
BACKGROUND: While @entity1871 addition to @entity172 mitigates @entity1204 risk, the magnitude of the effect on incidence, specific @entity1204 histologies, and @entity1204 mortality remains unsettled. These issues were assessed by analyses after extended follow-up of the @entity1 's Health Initiative (WHI) randomized clinical trial evaluating continuous combined @entity172 plus @entity1871 use. METHODS: The WHI enrolled 16 608 postmenopausal @entity1 into a randomly assigned, double-blind, placebo-controlled trial. @entity1 age 50 to 79 years with intact uteri with normal endometrial biopsy at entry were randomly assigned to once-daily 0.625mg conjugated @entity1641 @entity172 plus 2.5mg @entity11796 (n = 8506) as a single pill or matching placebo (n = 8102). Follow-up beyond the original trial completion date required reconsent, obtained from 12 788 (83%) of surviving @entity1 . Analyses were by intent-to-treat. All statistical tests were two-sided. RESULTS: After 5.6 years' median intervention and 13 years' median cumulative follow-up, there were fewer @entity1204 in the combined hormone therapy compared with the placebo group (66 vs 95 case @entity1 , yearly incidence, 0.06% vs 0.10%; hazard ratio [HR] = 0.65, 95% confidence interval [CI] = 0.48 to 0.89, P = .007). While there were somewhat fewer @entity1204 during intervention (25 vs 30, respectively; HR = 0.77, 95% CI = 0.45 to 1.31), the difference became statistically significant postintervention (41 vs 65, respectively; HR = 0.59, 95% CI = 0.40 to 0.88, P = .008), but hazard ratios did not differ between phases (P difference = .46). There was a statistically nonsignificant reduction in @entity204 from @entity1204 in the @entity172 plus @entity1871 group (5 vs 11 @entity204 , HR = 0.42, 95% CI = 0.15 to 1.22). CONCLUSION: In postmenopausal @entity1 , continuous combined @entity172 plus @entity1871 decreases @entity1204 incidence.
